Small and Rural

The latest report from AIR340B, a group financed and backed by the pharmaceutical industry, continues to misrepresent a program with a successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive…
Fifty-seven senators Friday urged the Centers for Medicare & Medicaid Services (CMS) to “carefully consider stakeholder feedback” before the agency finalizes its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. “The long-term success of the…
Fifty-seven senators Friday urged the Centers for Medicare & Medicaid Services to “carefully consider stakeholder feedback" before the agency finalizes its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. "The long-term success of the 340B…
The 340B Drug Pricing Program “has enabled hospitals and health systems to support and expand access and services consistent with their mission and the program’s original and ongoing charge,” the AHA and Association of American Medical Colleges today told leaders of the House Energy and Commerce…
The Centers for Medicare & Medicaid Services today officially withdrew its proposal to test new models for how Medicare Part B pays for prescription drugs provided in physician offices and hospital outpatient departments.
Two hundred twenty-eight members of the House of Representatives yesterday urged the Centers for Medicare & Medicaid Services to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.
The Health Resources and Services Administration today delayed to July 1, 2018 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. “We are delaying the effective date of the Jan.
A bipartisan group of 228 House lawmakers yesterday urged the Centers for Medicare & Medicaid Services (CMS) to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.